Department of Surgery, Medical University of Vienna, Vienna, Austria.
Int J Obes (Lond). 2009 Nov;33(11):1257-64. doi: 10.1038/ijo.2009.160. Epub 2009 Aug 18.
Insulin resistance in visceral obesity is substantially driven by adipose tissue inflammation, particularly by macrophages accumulating in obese adipose tissue. In contrast, adipose tissue macrophages express the hemoglobin scavenger receptor (CD163) and heme oxygenase-1 (gene: HMOX1) that together protect from oxidative stress. Our aim was to evaluate the expression of CD163 and HMOX1 in intra-abdominal visceral (omental) and subcutaneous adipose tissue as well as circulating soluble CD163 concentrations in human obesity and its association with adipose tissue inflammation, body fat distribution and insulin resistance.
CD163, HMOX1 and CD68 mRNA expression in visceral and subcutaneous adipose tissue, serum concentration of soluble CD163 in morbidly obese patients (body mass index (BMI) >40 kg m(-2)), who underwent laparoscopic surgery for gastric banding (n=20), matched for age and sex to controls (BMI<30 kg m(-2); n=20) was analyzed.
CD163 expression was highly upregulated in human adipose tissue and soluble CD163 serum concentration was elevated in obese vs lean subjects. HMOX1 was upregulated in adipose tissue by obesity as well and expressed predominantly in macrophages. Although CD163 expression strictly correlated with macrophage abundance, HMOX1 was additionally upregulated within macrophages. This upregulation was significantly lower in visceral compared with subcutaneous adipose tissue. Strikingly, relative visceral adipose tissue expression of HMOX1 negatively correlated with waist-to-hip ratio and the homeostasis model assessment of insulin resistance (both P=0.024).
Visceral obesity is associated with defective upregulation of heme oxygenase-1 in visceral adipose tissue. A lack of this antioxidative and anti-inflammatory enzyme in visceral adipose tissue could contribute to the development of insulin resistance.
内脏肥胖中的胰岛素抵抗主要由脂肪组织炎症驱动,尤其是由积聚在肥胖脂肪组织中的巨噬细胞引起。相比之下,脂肪组织中的巨噬细胞表达血红蛋白清除受体(CD163)和血红素加氧酶-1(基因:HMOX1),它们共同保护免受氧化应激。我们的目的是评估 CD163 和 HMOX1 在人体肥胖症中的内脏(网膜)和皮下脂肪组织中的表达,以及循环可溶性 CD163 浓度及其与脂肪组织炎症、体脂分布和胰岛素抵抗的关系。
分析了接受腹腔镜胃带手术(BMI>40 kg m(-2))的病态肥胖患者(n=20)与年龄和性别匹配的对照组(BMI<30 kg m(-2);n=20)内脏和皮下脂肪组织中 CD163、HMOX1 和 CD68 mRNA 的表达以及血清可溶性 CD163 浓度。
CD163 在人体脂肪组织中高度上调,肥胖患者的血清可溶性 CD163 浓度升高。肥胖也会使 HMOX1 在脂肪组织中上调,并主要在巨噬细胞中表达。尽管 CD163 的表达与巨噬细胞丰度严格相关,但 HMOX1 在巨噬细胞中也被上调。这种上调在内脏脂肪组织中明显低于皮下脂肪组织。值得注意的是,相对内脏脂肪组织中 HMOX1 的表达与腰臀比和胰岛素抵抗的稳态模型评估呈负相关(均 P=0.024)。
内脏肥胖与内脏脂肪组织中血红素加氧酶-1的上调缺陷有关。这种抗氧化和抗炎酶在内脏脂肪组织中的缺乏可能导致胰岛素抵抗的发展。